Roche, Kosan to continue KOS-862 Phase II

Following an interim analysis, KOSN said it and partner Roche (SWX:ROCZ) will continue to full enrollment a Phase II trial of KOS-862 (Epothilone D) to treat metastatic breast cancer. KOSN would not disclose the primary endpoint or say whether it had been met. However, KOSN said the trial design requires that the "primary objective" be met in stage one before proceeding to stage two. Interim results will be presented at the American Society of Clinical Oncology (ASCO) meeting in May. ...